Research programme: VEGF receptor antagonists - AstraZeneca

Drug Profile

Research programme: VEGF receptor antagonists - AstraZeneca

Alternative Names: AZD 9935

Latest Information Update: 13 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Jan 2008 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
  • 17 Dec 2007 AZD 9935 is still in preclinical trials for Solid tumours in the United Kingdom
  • 26 Jul 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top